Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
Authors
Keywords
-
Journal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-03
DOI
10.1007/s10928-023-09884-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of and insights from systems pharmacology models of antibody‐drug conjugates
- (2022) Inez Lam et al. CPT-Pharmacometrics & Systems Pharmacology
- The therapeutic window of antibody drug conjugates: A dogma in need of revision
- (2022) Raffaele Colombo et al. CANCER CELL
- ADME and DMPK considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs)
- (2022) Kevin Beaumont et al. XENOBIOTICA
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
- (2021) Kohei Shitara et al. Gastric Cancer
- Antibody‒drug conjugates: Recent advances in linker chemistry
- (2021) Zheng Su et al. Acta Pharmaceutica Sinica B
- Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
- (2021) Gail Lewis Phillips et al. BREAST CANCER RESEARCH AND TREATMENT
- An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens
- (2020) Bruna Menezes et al. AAPS Journal
- Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
- (2020) Hiromi Okamoto et al. XENOBIOTICA
- Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1
- (2020) Alison Betts et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
- (2019) Takashi Nakada et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach
- (2019) Katherine Kay et al. AAPS Journal
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach
- (2018) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
- (2017) Toshihiko Doi et al. LANCET ONCOLOGY
- Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1)
- (2016) Aman P. Singh et al. AAPS Journal
- Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
- (2016) Alison M. Betts et al. AAPS Journal
- Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design
- (2016) Katie F. Maass et al. AAPS Journal
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Quantitative Systems Pharmacology: A Case for Disease Models
- (2016) CJ Musante et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography
- (2016) Su Hyun Lee et al. MEDICINE
- SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
- (2015) K. J. Hamblett et al. CANCER RESEARCH
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
- (2015) M. M. C. van der Lee et al. MOLECULAR CANCER THERAPEUTICS
- A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
- (2015) Christina Vasalou et al. PLoS One
- High-Affinity Accumulation of a Maytansinoid in Cells via Weak Tubulin Interaction
- (2015) Victor S. Goldmacher et al. PLoS One
- A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate
- (2014) Dhaval K. Shah et al. AAPS Journal
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients
- (2013) Matthew D. Onsum et al. AMERICAN JOURNAL OF PATHOLOGY
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
- (2013) Nahor Haddish-Berhane et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
- (2013) YORIKO YAMASHITA-KASHIMA et al. ONCOLOGY REPORTS
- A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
- (2012) Brendan C. Bender et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin
- (2012) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
- (2012) H. K. Erickson et al. MOLECULAR CANCER THERAPEUTICS
- Human Tumor Xenografts: The Good, the Bad, and the Ugly
- (2012) Richard A Morgan MOLECULAR THERAPY
- Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
- (2011) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
- (2010) Nelson L. Jumbe et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- A practical guide to understanding Kaplan-Meier curves
- (2010) Jason T. Rich et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
- (2009) M. M. Schmidt et al. MOLECULAR CANCER THERAPEUTICS
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
- (2008) Greg M. Thurber et al. ADVANCED DRUG DELIVERY REVIEWS
- Serum HER-2/neuand relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
- (2008) Suhail M. Ali et al. CANCER
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- A methodology for performing global uncertainty and sensitivity analysis in systems biology
- (2008) Simeone Marino et al. JOURNAL OF THEORETICAL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now